Compare APYX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | CNTB |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.2M | 128.6M |
| IPO Year | 1987 | 2021 |
| Metric | APYX | CNTB |
|---|---|---|
| Price | $3.51 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 57.1K | ★ 152.2K |
| Earning Date | 11-06-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,902,000.00 | $762,000.00 |
| Revenue This Year | $8.41 | N/A |
| Revenue Next Year | $7.01 | $24,739.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $0.51 |
| 52 Week High | $4.44 | $3.28 |
| Indicator | APYX | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 51.39 |
| Support Level | $3.35 | $2.50 |
| Resistance Level | $3.65 | $2.89 |
| Average True Range (ATR) | 0.16 | 0.24 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 25.00 | 59.48 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.